Bio-View Ltd

Tel Aviv Stock Exchange BIOV.TA

Bio-View Ltd Receivables for the year ending December 31, 2023: USD 2.04 M

Bio-View Ltd Receivables is USD 2.04 M for the year ending December 31, 2023, a 35.85% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.
  • Bio-View Ltd Receivables for the year ending December 31, 2022 was USD 1.50 M, a 5.63% change year over year.
  • Bio-View Ltd Receivables for the year ending December 31, 2021 was USD 1.42 M, a 41.84% change year over year.
  • Bio-View Ltd Receivables for the year ending December 31, 2020 was USD 1.00 M, a -19.37% change year over year.
  • Bio-View Ltd Receivables for the year ending December 31, 2019 was USD 1.24 M, a 51.93% change year over year.
Key data
Date Receivables Inventory Goodwill Total Assets
Market news
Loading...
SV Wall Street
Tel Aviv Stock Exchange: BIOV.TA

Bio-View Ltd

CEO Mr. Daniel Klain
IPO Date March 12, 2006
Location Israel
Headquarters 3 Pekeris Street
Employees 33
Sector Healthcare
Industries
Description

Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. Its products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH samples in real-time; and Allegro Plus, an automatic fluorescent imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an imaging and analysis platform that include an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; Solo Touch Workstation, a stand-alone workstation with advanced review and analysis tools; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases. Bio-View Ltd has a partnership agreement with ANGLE plc to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 2000 and is headquartered in Rehovot, Israel.

StockViz Staff

February 6, 2025

Any question? Send us an email